LeiZhengMD

Oncology • San Antonio, TX

UT Health San Antonio – Executive Director, Mays Cancer Center, Vice President for Oncology

Join to view full profile

Dr. Zheng is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zheng's full profile

Already have an account?

Office
7979 Wurzbach Road
Mail Code 8026, Office U632A
San Antonio, TX 78229

Summary

Dr. Lei Zheng is an oncologist in San Antonio, TX. He received his medical degree from Peking Union Medical College and has been in practice 21 years. He also speaks multiple languages, including Chinese (Mandarin). He is experienced in pancreatic cancer, immunotherapy, gastroenterology, oncology, and personalized medicine. He has more than 150 publications and over 10,000 citings.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 2003 - 2006
Peking Union Medical CollegeClass of 1996

Certifications & Licensure

MD State Medical License 2006 - 2025
PA State Medical License 2020 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine Start of enrollment: 2010 Apr 20
ACTIVE_NOT_RECRUITING
PHASE2
Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma Start of enrollment: 2013 Jan 01
COMPLETED
PHASE2
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer Start of enrollment: 2016 Jul 18
COMPLETED
PHASE2
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma Start of enrollment: 2019 Jun 04
RECRUITING
PHASE2
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. Start of enrollment: 2019 Dec 12
COMPLETED
PHASE1, PHASE2
Join now to see all

Publications & Presentations

PubMed

1 citations
Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and Stereota...
Colin S Hill, Rose Parkinson, Elizabeth M Jaffee, Elizabeth Sugar, Lei Zheng
International Journal of Radiation Oncology, Biology, Physics. 2025-03-15
Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database.
Abrahm Levi, Edik Blais, John Davelaar, Matthew I Ebia, Angela Minasyan
The Oncologist. 2025-03-10
Clinical development of immuno-oncology therapeutics.
Jianxin Wang, Qi Chen, Qiang Shan, Tingbo Liang, Patrick Forde
Cancer Letters. 2025-03-06

Press Mentions

Mays Cancer Center Earns Gold Standard for Excellence in Radiation OncologyFebruary 26th, 2025
Mays Cancer Center Continues Collaboration with American Cancer Society to Expand Lung Cancer ScreeningsFebruary 24th, 2025
Renowned Oncologist, Zheng, Brings $500,000 UT System STARs Award to UT Health San AntonioJanuary 10th, 2025
Join now to see all

Other Languages

Chinese (Mandarin)

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/lei-zheng